Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial

OBJECTIVES: To examine whether baseline anti-cyclic citrullinated peptide-2 (CCP2) antibody status and concentration correlated with clinical outcomes in patients treated with abatacept or adalimumab on background methotrexate (MTX) in the 2-year AMPLE (Abatacept versus adaliMumab comParison in bioL...

Descripción completa

Detalles Bibliográficos
Autores principales: Sokolove, Jeremy, Schiff, Michael, Fleischmann, Roy, Weinblatt, Michael E, Connolly, Sean E, Johnsen, Alyssa, Zhu, Jin, Maldonado, Michael A, Patel, Salil, Robinson, William H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819608/
https://www.ncbi.nlm.nih.gov/pubmed/26359449
http://dx.doi.org/10.1136/annrheumdis-2015-207942

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819608/
https://www.ncbi.nlm.nih.gov/pubmed/26359449
http://dx.doi.org/10.1136/annrheumdis-2015-207942

Ejemplares similares